期刊文献+

LT_3S与急性心力衰竭患者病情的相关性及其对短期预后的预测价值 被引量:4

Prognostic impact of low triiodothyronine syndrome on acute heart failure patients
下载PDF
导出
摘要 目的:观察和分析低三碘甲状腺原氨酸综合征(LT3S)对判断急性心力衰竭(AHF)患者病情危重程度和预测短期内死亡风险的临床价值。方法:入选240例AHF患者,对其进行疾病严重程度指数APACHE II评分,检测其脑钠尿肽(BNP)水平、甲状腺功能。统计患者住院期间病死率,电话随访患者出院6个月后的生存情况。结果:入选240例AHF患者中,并发的患者70例,发生率为29.2%;并发LT3S与并发非LT3S AHF患者间APACHE II评分、BNP水平、住院期间病死率和随访期间病死率差异均有统计学意义[(24±6)vs.(20±6);(784±188)mg/L vs.(697±200)mg/L;17.1%vs.7.6%;11.3%vs.3.4%,均P<0.05]。Cox回归风险比例模型分析:游离三碘甲状腺原氨酸(FT3)水平、APACHE II评分和BNP水平是AHF患者短期内死亡的影响因素(标准偏回归系数=-0.872,HR=0.683,95%CI:0.536-0.847,P<0.05;标准偏回归系数=1.531,HR=1.257,95%CI:1.317-1.864,P<0.05;标准偏回归系数=0.417,HR=0.997,95%CI:0.922-1,P<0.05)。受试者工作特征曲线(ROC)下面积(AUC)分析:APACHE II评分的AUC大于BNP水平和FT3水平的AUC;而BNP水平和FT3水平的AUC间的差异无统计学意义(0.893,95%CI:0.831-0.965;0.720,95%CI:0.640-0.806;0.698,95%CI:0.586-0.751)。结论:AHF患者伴LT3S的诊断,对预测患者的病情危重程度和预后有重要价值。 AIM: To determine the morbidity of low triiodothyronine syndrome in patients with acute heart failure (AHF) and to evaluate the effect of low triiodothyronine syndrome on disease severity and prognosis. METHODS: Thyroid hormone levels, APACHE II scores and BNP levels were assessed in 240 consecutive patients hospitalized for AHF. Mortality during hospitalization was calculated and survival 6 months after discharge was followed-up by telephone inquiry. RESULTS: Seventy (29. 2% ) of the 240 patients with AHF had low thyroid hormone syndrome and the mortality rate during hospitalization and after discharge in this group was higher than in the normal T3 group (17. 1% vs. 7. 6%, P 〈0. 05; 11.3% vs. 3.4%, P 〈0. 05). APACHE II scores and BNP levels were higher in low thyroid hormone syndrome group compared with those in normal T3 group [24±6 vs. 20±6; (784 ± 188) mg/L vs. (697±200) mg/L]. In a multivariate Cox proportional hazards model, FT3 levels, APACHE II scores and BNP levels were independent predictors of early mortality in patients in AHF ( HR = 0. 683, 95% CI: 0. 536 - 0. 847, P〈O. 05; HR=1.257, 95%CI: 1.317-1.864, P〈0.05; HR =0.997, 95%CI: 0.922-1, P〈 0. 05). Area under the curve for APACHE II scores was higher than for FT3 and BNP levels. However,there was no significant difference in area under the curve between FT3 and BNP levels (0. 893, 95% CI: 0. 831 -0.965; 0.720, 95%CI: 0. 640-0. 806; 0.698, 95%CI: 0. 586-0.751). CONCLUSION: Diagnosis of AHF complicated with low T3 syndrome is important in evaluating disease severity and predicting the prognosis.
出处 《心脏杂志》 CAS 2015年第1期48-50,57,共4页 Chinese Heart Journal
关键词 心力衰竭 急性 低三碘甲状腺原氨酸综合征 病死率 APACHEII评分 acute heart failure low triiodothyronine syndrome motality APACHE II score
  • 相关文献

参考文献1

二级参考文献16

  • 1Braunwald E. Biomakers in heart failure[ J]. N Engl J Med, 2008, 358(20) :2148 -2159.
  • 2John G, Richard W, Kim M, et al. N-Terminal Pro-B-Type Natriuretic Peptide-Guided treatment for chronic heart failure [ J]. J Am Coll Cardiol, 2010, 55(1):53-60.
  • 3Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive tbr 1-year mortality in patients with acute destabilized heart failure[ J ]. Clin Chem, 2008, 54(4) :752-756.
  • 4Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with aeute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study[ J ]. J Am Coll Cardiol, 2007, 50(7) :607 -613.
  • 5Villacorta H, Masetto AC, Mesquita ET. C-Reactive Protein: an inflammatory marker with prognostic value in patients with decompensated heart failure[ J ]. Arq Bras Cardiol, 2007, 88 ( 5 ) :585 - 589.
  • 6Tamariz L, Hare JM. lntlammatory cytokines in heart failure: roles in aetiology and utility as biomarkers[ J]. Eur Heart J, 2010, 31 (7) :768 - 770.
  • 7Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart fallure [ J ]. N Engl J Med, 2008, 358 ( 20 ) : 2117 -2126.
  • 8Lee HG, Bae WH, Kim SH, et al. The clinical usefulness of cardiac troponin i as a marker for severity in patients with congestive heart failure[J]. Korean Circ J, 2000, 30(6) :724 -728.
  • 9Chatzikyriakou SV, Tziakas DN, Chalikias GK, et al. Chronie heart failure patients with high eollagen type 1 degradation marker levels bene? t more with ACE-inhibitor therapy [ J ]. Ettr J Pharmacol, 2010, 628( 1 -3) :164 - 170.
  • 10Tang WH, Shrestha K, Martin MG, et al. Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure [J]. J Card Fail, 2010, 16(8) :635 -640.

共引文献1

同被引文献28

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部